1
|
Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabrò L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 2021; 44:1719-1726. [PMID: 33367977 PMCID: PMC8285335 DOI: 10.1007/s40618-020-01480-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 11/27/2020] [Indexed: 02/05/2023]
Abstract
PURPOSE Immunotherapy against immune checkpoints has significantly improved survival both in metastatic and adjuvant setting in several types of cancers. Thyroid dysfunction is the most common endocrine adverse event reported. Patients who are at risk of developing thyroid dysfunction remain to be defined. We aimed to identify predictive factors for the development of thyroid dysfunction during immunotherapy. METHODS This is a retrospective study including a total of 68 patients who were treated with immune checkpoint inhibitors (ICIs) for metastatic or unresectable advanced cancers. The majority of patients were treated with anti-PD1 drugs in monotherapy or in combination with anti-CTLA4 inhibitors. Thyroid function and anti-thyroid antibodies, before starting immunotherapy and during treatment, were evaluated. Thyroid ultrasound was also performed in a subgroup of patients at the time of enrolment in the study. RESULTS Eleven out of 68 patients (16.1%) developed immune-related overt thyroid dysfunction. By ROC curve analysis, we found that a serum TSH cut-off of 1.72 mUI/l, at baseline, had a good diagnostic accuracy in identifying patients without overt thyroid dysfunction (NPV = 100%, p = 0.0029). At multivariate analysis, both TSH and positive anti-thyroid antibodies (ATAbs) levels, before ICIs treatment, were independently associated with the development of overt thyroid dysfunction during immunotherapy (p = 0.0001 and p = 0.009, respectively). CONCLUSIONS Pre-treatment serum TSH and ATAbs levels may help to identify patients at high risk for primary thyroid dysfunction. Our study suggests guidance for an appropriate timely screening and for a tailored management of thyroid dysfunctions in patients treated with ICIs.
Collapse
Affiliation(s)
- L Brilli
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy
| | - R Danielli
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy
| | - M Campanile
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy
| | - C Secchi
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy
| | - C Ciuoli
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy
| | - L Calabrò
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy
| | - T Pilli
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy
| | - A Cartocci
- Department of Medical Biotechnologies, University of Siena, Siena, 53100, Italy
| | - F Pacini
- Department of Biomedical Sciences, Humanitas Clinical and Research Center, IRCCS, 20089, Rozzano, Milan, Italy
| | - A M Di Giacomo
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100, Siena, Italy
| | - M G Castagna
- Endocrinology Unit, Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena, 53100, Italy.
- Department of Medical Sciences, University of Siena, Policlinico Santa Maria Alle Scotte, Viale Bracci 16, 53100, Siena, Italy.
| |
Collapse
|
2
|
Calabro L, Morra A, Giannarelli D, Amato G, Bertocci E, D'Incecco A, Danielli R, Brilli L, Giannini F, Altomonte M, Di Giacomo A, Maio M. MA 19.02 Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.635] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Calabrò L, Morra A, Fonsatti E, Giannarelli D, Annesi D, Bertocci E, Danielli R, Altomonte M, Di Giacomo A, Maio M. A phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv514.06] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Di Giacomo A, Ascierto P, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26:798-803. [DOI: 10.1093/annonc/mdu577] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911-5. [PMID: 24067719 DOI: 10.1093/annonc/mdt376] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced melanoma. However, because previous clinical trials with ipilimumab have excluded patients with uveal melanoma, data in this patient population are limited. PATIENTS AND METHODS Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses. Tumour assessments were conducted at baseline and after completion of treatment and patients were monitored throughout for adverse events. RESULTS Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%. With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months. The 1-year rates of OS and PFS were 31% and 11%, respectively. The safety profile of ipilimumab was similar to that in patients with cutaneous melanoma. CONCLUSIONS These data suggest ipilimumab 3 mg/kg is a feasible option in pre-treated patients with metastatic uveal melanoma. Evidence of disease control and a 1-year survival rate of 31% indicate the need for further investigation in randomised, controlled trials to determine the optimal timing and use of ipilimumab in this patient population.
Collapse
Affiliation(s)
- M Maio
- Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Tuscan Cancer Institute, Siena
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Altomonte M, Queirolo P, Testori A, Ascierto P, Danielli R, Giacomo AD, Sileni VC, Del Vecchio M, Ridolfi R, Maio M. 9328 The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71972-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
7
|
Danielli R, Queirolo P, Testori A, Plummer R, Razi E, Sileni VC, Calabrò L, Giacomo AD, Ridolfi R, Maio M. 9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71959-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Di Giacomo A, Danielli R, Calabrò L, Guidoboni M, Miracco C, Biagioli M, Mazzei M, Altomonte M, Maio M. Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20002 Background: Effective anti-tumor responses are being observed in metastatic melanoma (MM) patients (pts) with the anti-CTLA-4 antibody Ipilimumab (Ipi) in clinical trials; however no data support the feasibility and clinical effectiveness of Ipi use in the daily practice. We report a single Institution experience utilizing Ipi within a compassionate program for MM pts. Methods: 27 stage III (2) or IV (25) pts (14 males, 13 females), median age 55 (23–77) years, ECOG performance status 0- 1, with MM (23 cutaneous, 3 uveal, 1 mucosal) progressing to 3 median (1–5) systemic therapies for metastatic disease received Ipi. Eight pts had evidence (6) or history (2) of brain metastases and 11 elevated (>1x upper limit of normal [ULN]) LDH. In the induction phase (IF) pts received Ipi (10 mg/kg i.v.) q3 weeks (wks) x 4 cycles; after a 12 wks rest treatment was repeated q12 wks in the maintenance phase (MF). Tumor assessment (TA) per modified World Health Organization criteria was performed at baseline, week (wk) 12 (±2) and wk 24, then every 12 wks. Adverse Events (AE) and immune related AE (irAE) were collected according to Common Terminology Criteria for Adverse Events version 3.0. Results: All pts received at least one Ipi dose, and 18/27 completed the IF. Of the remaining 9 pts, 4 are completing the IF and 5 were withdrawn for AE severity (3 pts) or disease progression (2 pts). Eight pts entered the MF. TA at wk 12 showed partial response (PR) in 1/18 or stable disease (SD) in 5/18 pts. TA at wk 24 showed PR and SD in 3/8 and 5/8 pts, respectively, with an ongoing clinical benefit (SD + PR + CR) of 34% (8/23 pts); these pts are still on treatment. Slow, steady declines in tumor volume and appearance of new lesions with subsequent shrinking of total tumor burden has been observed. One patient had Grade 3 AE (myocardial infarction) and 2 pts had Grade 3 irAE (diarrhoea). Excluding pts who are in IF, to date median overall survival is 27 wks (19–39). Conclusions: Ipi treatment is feasible, safe and clinically effective also in the common daily practice and in heavily pretreated, progressing, MM pts. A sizable proportion of these pts experiences durable clinical benefit. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Di Giacomo
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - R. Danielli
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - L. Calabrò
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - M. Guidoboni
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - C. Miracco
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - M. Biagioli
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - M. Mazzei
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - M. Altomonte
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| | - M. Maio
- University Hospital of Siena - ITT, Siena, Italy; University Hospital of Siena - ITT - CRO, Siena - Aviano, Italy
| |
Collapse
|